Lumeda Reports Progress In Clinical Evaluation Of Its Intraoperative Photodynamic Therapy
Lumeda Inc. ("Lumeda"), a biophotonics systems company formed to advance photodynamic therapy (PDT) for treating cancer, today announced the completion of a phase 1 clinical by Roswell Park ...
ALS News Today5h
New ALS trial data show nearly 2-year survival benefit with NP001
A 22-month survival benefit was seen for a subset of ALS patients whose disease did not progress when treated with NP001 in ...
Daily6h
Sun Pharma Labs Gets CDSCO Panel Nod Phase-III clinical trial of Semaglutide solution for injection
Sun Pharma Labs has got the go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard ...
PharmaTimes6h
Vedanta Biosciences reveals Phase 2 VE303 results
Vedanta Biosciences has published additional results from its Phase 2 CONSORTIUM study for VE303, a potential first-in-class ...
NanoViricides Engages CRO for Phase II Clinical Trial
NanoViricides, Inc. (NYSE American:NNVC) (the “Company”) today announced that it has engaged a Clinical Research Organization (CRO) to conduct a Phase II clinical trial advancing its broad-spectrum ...
BioArctic: FDA approves IV maintenance dosing of Leqembi (lecanemab-irmb) for the treatment of early Alzheimer's Disease in the US
BioArctic AB (publ) (NASDAQ STOCKHOLM: BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has approved BioArctic's partner Eisai's ...
Biogen Inc.: FDA Approves LEQEMBI (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment Alzheimer's disease progression does not stop after plaque clearance; ongoing treatment with ...